|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,518.00 JPY | +0.83% |
|
+1.32% | +8.06% |
| 09:34am | Takeda Canada: British Columbia reimburses Fruzaqla for treatment of metastatic colorectal cancer | RE |
| 12-07 | Takeda, Protagonist Report One-Year Rusfertide Gains in PV trial | MT |
EPS & Dividend: Takeda Pharmaceutical Company Limited
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Dividend per Share 2 | 180 | 180 | 180 | 188 | 196 | 200 | 203.3 | 208.6 |
| Rate of return | 4.52% | 5.15% | 4.14% | 4.49% | 4.44% | 4.43% | 4.5% | 4.62% |
| EPS 2 | 240.7 | 147.1 | 204.3 | 92.09 | 68.36 | 111.3 | 183.9 | 203.7 |
| Distribution rate | 74.8% | 122% | 88.1% | 204% | 287% | 180% | 111% | 102% |
| Reference price 2 | 3,985.00 | 3,498.00 | 4,350.00 | 4,184.00 | 4,413.00 | 4,518.00 | 4,518.00 | 4,518.00 |
| Nbr of stocks (in thousands) | 1,563,355 | 1,550,444 | 1,554,530 | 1,568,924 | 1,529,498 | 1,579,594 | - | - |
| Announcement Date | 5/11/21 | 5/11/22 | 5/11/23 | 5/9/24 | 5/8/25 | - | - | - |
Past dividends: Takeda Pharmaceutical Company Limited
| 2025-09-28 | Interim Payment 100 JPY |
| 2025-03-27 | Final Payment 98 JPY |
| 2024-09-26 | Interim Payment 98 JPY |
| 2024-03-27 | Final Payment 94 JPY |
| 2023-09-27 | Interim Payment 94 JPY |
| 2023-03-29 | Final Payment 90 JPY |
| 2022-09-28 | Interim Payment 90 JPY |
| 2022-03-29 | Final Payment 90 JPY |
| 2021-09-28 | Interim Payment 90 JPY |
| 2021-03-29 | Final Payment 90 JPY |
| 2020-09-28 | Interim Payment 90 JPY |
| 2020-03-29 | Final Payment 90 JPY |
| 2019-09-26 | Interim Payment 90 JPY |
| 2019-03-26 | Final Payment 90 JPY |
| 2018-09-25 | Interim Payment 90 JPY |
| 2018-03-27 | Final Payment 90 JPY |
| 2017-09-26 | Interim Payment 90 JPY |
| 2017-03-28 | Final Payment 90 JPY |
| 2016-09-27 | Interim Payment 90 JPY |
| 2016-03-28 | Final Payment 90 JPY |
Upcoming events: Takeda Pharmaceutical Company Limited
| Dividend Yield (N) | Dividend Yield (N+1) | P/E (N) | Price to Book (N) | EV / Sales (N) | ||
|---|---|---|---|---|---|---|
 | 4.46% | 4.54% | 40.24x | 1.03x | 2.45x | |
| 0.55% | 0.62% | 46.44x | 34.97x | 15.35x | |
| 2.41% | 2.49% | 20.48x | 6.52x | 5.68x | |
| 2.87% | 2.99% | 52.06x | 3103x | 7.52x | |
| 3.07% | 3.13% | 18.68x | 6.67x | 4.69x | |
| 1.77% | 1.87% | 27.43x | 6.19x | 5.19x | |
| 3.03% | 3.16% | 18.61x | 5.83x | 5.02x | |
| 3.23% | 3.27% | 12.96x | 4.66x | 4.23x | |
| 3.68% | 3.61% | 13.72x | 7.45x | 4.91x | |
| 2.94% | 3.11% | 25.64x | 19.38x | 6.05x | |
| Average | 2.8% | 2.88% | 27.62x | 319.57x | 6.11x | |
| Weighted average by Cap. | 2.21% | 2.28% | 31.12x | 375.92x | 8.19x |
Year-on-year evolution of the Yield
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Estimates Revisions
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Annual Profit -
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition